Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China

被引:0
作者
Lv, Wei [1 ]
Du, Chong [1 ]
Zhang, Yinbing [1 ]
Wu, Fei [1 ]
Jin, Yaofeng [2 ]
Chen, Xi [1 ]
Liu, Xuan [1 ]
Feng, Cong [1 ]
Ma, Xingcong [1 ]
Zhang, Shuqun [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Pathol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; PIK3CA mutation; Northwest China; Prognosis; Targeted therapy; PI3K-AKT-MTOR PATHWAY; INSULIN-SECRETION; HIGH-FREQUENCY; PI3K PATHWAY; GENE; METABOLISM; RESISTANCE; 3-KINASES; SURVIVAL;
D O I
10.1016/j.prp.2022.154063
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Purpose: Multiple studies on PIK3CA mutations in breast cancer (BC) had been performed, which showed the controversial results among different countries and races even those from the same country. The present study aimed to explore the PIK3CA gene mutation status in BC patients in Northwest China and reveal the relationship between PIK3CA mutations and clinicopathological features along with prognosis.Materials and methods: 1002 BC patients from Northwest China were recruited in this study, genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues, and hotspot mutations in the exon 9 and 20 of PIK3CA gene were detected by ARMS-PCR.Results: PIK3CA mutations were found in 31.2% (313/1002) of BC patients, among them 66.1% were mutations in exon 20% and 32.6% were mutations in exon 9. H1047R was the most common mutation type, accounting for 56.5% of the total mutated samples. Significant correlations were observed between PIK3CA mutation status and age (P = 0.035), histopathologic types (P = 0.004), pathological grade (P = 0.013), ER positivity (P < 0.001), PR positivity (P < 0.001), molecular subtypes (P = 0.004) and family history (P = 0.007). Cox multivariate analysis showed that patients with mutations in exon 9 or 20 had shorter DFS and OS than wild-type patients. Those with exon 9 mutations subgroup had the worst prognosis. Interestingly, patients with H1047L mutation had the best prognosis than others. Conclusion: PIK3CA mutations could be used as an indicator of clinical outcome or targeted therapy for multiple breast cancer subgroups in Northwest China.
引用
收藏
页数:12
相关论文
共 45 条
  • [11] Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients
    Chen, Li
    Yang, Liu
    Yao, Ling
    Kuang, Xia-Ying
    Zuo, Wen-Jia
    Li, Shan
    Qiao, Feng
    Liu, Yi-Rong
    Cao, Zhi-Gang
    Zhou, Shu-Ling
    Zhou, Xiao-Yan
    Yang, Wen-Tao
    Shi, Jin-Xiu
    Huang, Wei
    Hu, Xin
    Shao, Zhi-Ming
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [12] Cancer incidence and mortality in China, 2007
    Chen, Wan-qing
    Zeng, Hong-mei
    Zheng, Rong-shou
    Zhang, Si-wei
    He, Jie
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (01) : 1 - 8
  • [13] Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer
    Chen, Xinyi
    Guo, Yonghai
    Ouyang, Tao
    Li, Jinfeng
    Wang, Tianfeng
    Fan, Zhaoqing
    Fan, Tie
    Lin, Benyao
    Xu, Ye
    Xie, Yuntao
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (05) : 1235 - 1242
  • [14] PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
    Cizkova, Magdalena
    Susini, Aurelie
    Vacher, Sophie
    Cizeron-Clairac, Geraldine
    Andrieu, Catherine
    Driouch, Keltouma
    Fourme, Emmanuelle
    Lidereau, Rosette
    Bieche, Ivan
    [J]. BREAST CANCER RESEARCH, 2012, 14 (01):
  • [15] Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
    Courtnay, Rupert
    Ngo, Darleen C.
    Malik, Neha
    Ververis, Katherine
    Tortorella, Stephanie M.
    Karagiannis, Tom C.
    [J]. MOLECULAR BIOLOGY REPORTS, 2015, 42 (04) : 841 - 851
  • [16] Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
    De, Pradip
    Sun, Yuling
    Carlson, Jennifer H.
    Friedman, Lori S.
    Leyland-Jones, Brian R.
    Dey, Nandini
    [J]. NEOPLASIA, 2014, 16 (01): : 43 - U95
  • [17] Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients
    Deng, Ling
    Zhu, Xuehua
    Sun, Yun
    Wang, Jiemin
    Zhong, Xiaorong
    Li, Jiayuan
    Hu, Min
    Zheng, Hong
    [J]. CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 128 - 140
  • [18] Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women
    Deng, Ling
    Chen, Jie
    Zhong, Xiao Rong
    Luo, Ting
    Wang, Yan Ping
    Huang, Hui Fen
    Yin, Li-Juan
    Qiu, Yan
    Bu, Hong
    Lv, Qing
    Zheng, Hong
    [J]. PLOS ONE, 2015, 10 (03):
  • [19] The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer
    Dumont, Amaury G.
    Dumont, Sarah N.
    Trent, Jonathan C.
    [J]. CHINESE JOURNAL OF CANCER, 2012, 31 (07) : 327 - 334
  • [20] The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
    Edge, Stephen B.
    Compton, Carolyn C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) : 1471 - 1474